Acetyl-l-carnitine for dementia
Open accessAbstract
BACKGROUND: Dementia is a common mental health problem affecting 5% of those over 65. Various pathological processes are linked to memory impairment in dementia, particularly those affecting the cholinergic neurotransmitter system. Acetyl-l-carnitine (ALC) is derived from carnitine and is described as having several properties which may be beneficial in dementia. This includes activity at cholinergic neurons, membrane stabilization and enhancing mitochondrial function. Work on the effects of ALC has been ongoing since the 1980s yet the efficacy of ALC in cognitive decline remains unclear. Early studies suggested a beneficial effect of ALC on cognition and behaviour in aging subjects. However, later, larger studies have not supported these findings. Some of the difficulties lie in the early and later studies differing widely in methodology and assessment tools used, and are therefore difficult to compare. ALC is not currently in routine clinical use. OBJECTIVES: The objective of this review is to establish whether Acetyl-l-carnitine is clinically effective in the treatment of people with dementia. SEARCH STRATEGY: The trials were identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 8 January 2003 using the terms acetyl-l-carnitine, l-carnitine acetyl ester, acetylcarnitine. SELECTION CRITERIA: All double-blind, randomized, trials involving people with dementia in which treatment with ALC was compared with a placebo group DATA COLLECTION AND ANALYSIS: Data were extracted by a reviewer (SH) and entered into Revman 4.1 software. Where possible intention-to-treat data were used, but most of the analyses were of completers (people who completed the study). MAIN RESULTS: There are 11 included trials, all of which had restricted the participants to people with Alzheimer's disease. All trials assessed the cognitive effects of ALC and in addition six considered severity of dementia, six considered functional ability and six considered clinical global impression. There were statistically significant treatment effects in favour of ALC at 12 and 24 weeks for the numbers showing improvement as determined by Clinical Global Impression, [OR 2.33, 95% CI 1.25 to 4.35, P<0.01] and [OR 3.91, 95% CI 1.32 to 11.54, P=0.01] but not as determined by the CIGIC at 52 weeks. There was no evidence of benefit for ALC in the areas of cognition, severity of dementia, functional ability or Clinical Global Impression as a continuous measure. Various adverse events were reported, but from the meta-analyses there were no statistically significant differences between treated and placebo groups. REVIEWER'S CONCLUSIONS: There is evidence for benefit of ALC on clinical global impression, but there was no evidence using objective assessments in any other area of outcome. Given the large number of comparisons made, the statistically significant result may be due to chance. At present there is no evidence to recommend its routine use in clinical practice. Although the intention of the review was to access ALC for the treatment of all dementias, the included trials had confined themselves to participants with Alzheimer's disease. Individual patient data may add to the findings, as would trials including other types of dementia and other outcomes (e.g. mood and caregiver quality of life). However, the evidence does not suggest that ALC is likely to prove an important therapeutic agent. More work on the pharmacokinetics of ALC in humans is also required.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Research findings are mixed regarding A-GPC's potential to impact cognition.
“Currently, research findings are mixed regarding A-GPC’s potential to impact cognition [7,8].”
From Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men (2024) · cites this paper as [8]
The Discussion reports mixed cognitive findings for acetyl-l-carnitine (ALC), not A-GPC. The Genazzani 1990 section mentions a study comparing ALC with l-alpha-glyceryl-phosphorylcholine, but gives no cognitive findings for the latter. Searches for A-GPC and l-alpha-glyceryl-phosphorylcholine found no passage assessing whether its effects on cognition are mixed. (LLM, conf=0.76)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2022) · doi:10.1176/appi.books.9780890425787 · Cited by 23,476 · see citing works
Diagnostic and Statistical Manual of Mental Disorders
&NA; (1988) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198802020-00022 · Cited by 12,603 · see citing works
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627 · see citing works
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565 · see citing works
The prevalence of dementia: A quantitative integration of the literature
Jorm, A. F., Korten, A. E., & Henderson, A. S. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb02906.x · Cited by 1,301 · see citing works
Pettegrew, J. W., Levine, J., & McClure, R. J. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000805 · Cited by 304 · see citing works
Long‐term acetyl‐L‐carnitine treatment in Alzheimer's disease
Spagnoli, A., Lucca, U., Menasce, G., Bandera, L., Cizza, G., Forloni, G., Tettamanti, M., Frattura, L., Tiraboschi, P., Comelli, M., et al. (1991) · Neurology · doi:10.1212/wnl.41.11.1726 · Cited by 232 · see citing works
Montgomery, S. A., Thal, L. J., & Amrein, R. (2003) · International Clinical Psychopharmacology · doi:10.1097/00004850-200303000-00001 · Cited by 209 · see citing works
Tomassini, V., Pozzilli, C., Onesti, E., Pasqualetti, P., Marinelli, F., Pisani, A., & Fieschi, C. (2003) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2003.11.005 · Cited by 165 · see citing works
Teaching tape for the motor section of the unified Parkinson's disease rating scale
Goetz, C. G., Stebbins, G. T., Chmura, T. A., Fahn, S., Klawans, H. L., & MARSDEN, C. D. (1995) · Movement Disorders · doi:10.1002/mds.870100305 · Cited by 154 · see citing works
Thal, L. J., Carta, A., Clarke, W. R., Ferris, S. H., Friedland, R. P., Petersen, R. C., Pettegrew, J. W., Pfeiffer, E., Raskind, M. A., Sano, M., et al. (1996) · Neurology · doi:10.1212/wnl.47.3.705 · Cited by 150 · see citing works
Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease
Pettegrew, J. W., Klunk, W. E., Panchalingam, K., Kanfer, J. N., & McClure, R. J. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)80001-8 · Cited by 148 · see citing works
Rosenthal, R. E., Williams, R., Bogaert, Y. E., Getson, P. R., & Fiskum, G. M. (1992) · Stroke · doi:10.1161/01.str.23.9.1312 · Cited by 137 · see citing works
Delaying the Mitochondrial Decay of Aging with Acetylcarnitine
Ames, B. N., & Liu, J. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1320.010 · Cited by 103 · see citing works
A 1-year controlled trial of acetyl- l -carnitine in early-onset AD
Thal, L. J., Calvani, M., Amato, A., & Carta, A. (2000) · Neurology · doi:10.1212/wnl.55.6.805 · Cited by 102 · see citing works
Impérato, A., Ramacci, M. T., & Angelucci, L. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90826-4 · Cited by 87 · see citing works
Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer's dementia
Rai, G. S., Wright, G., Scott, L. C., Beston, B., Rest, J., & Exton‐Smith, A. N. (1990) · Current Medical Research and Opinion · doi:10.1185/03007999009112690 · Cited by 84 · see citing works
Sano, M., Bell, K. L., Cote, L. M., Dooneief, G., Lawton, A., Legler, L., Marder, K. S., Naini, A., Stern, Y., & Mayeux, R. P. (1992) · Archives of Neurology · doi:10.1001/archneur.1992.00530350051019 · Cited by 82 · see citing works
Neuroprotective activity of acetyl‐L‐carnitine: Studies in vitro
Forloni, G., Angeretti, N., & Smiroldo, S. (1994) · Journal of Neuroscience Research · doi:10.1002/jnr.490370112 · Cited by 75 · see citing works
Brooks, J. O., Yesavage, J. A., Carta, A., & Bravi, D. (1998) · International Psychogeriatrics · doi:10.1017/s1041610298005304 · Cited by 61 · see citing works
Study of the efficacy and tolerability of L-acetylcarnitine therapy in the senile brain.
Bonavita, E. (1986) · PubMed · Cited by 56 · see citing works
Parnetti, L., Abate, G., Bartorelli, L., Cucinotta, D., Cuzzupoli, M., Maggioni, M., Villardita, C., & Senin, U. (1993) · Drugs & Aging · doi:10.2165/00002512-199303020-00006 · Cited by 55 · see citing works
Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression.
Garzya, G., Corallo, D., Fiore, A., Lecciso, G., Petrelli, G., & Zotti, C. (1990) · PubMed · Cited by 55 · see citing works
Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders.
Bella, R., Biondi, R., Raffaele, R., & Pennisi, G. (1990) · PubMed · Cited by 55 · see citing works
Selegiline versus L-acetylcarnitine in the treatment of Alzheimer-type dementia.
Campi, N., Gp, T., & Scarzella, L. (1990) · PubMed · Cited by 45 · see citing works
Decina, P., Caracci, G., Scapicchio, P. L., Goetz, C. G., Tanner, C. M., Cohen, J., Thelen, J. A., Carroll, V. S., Klawans, H. L., Fariello, R. G., et al. (1990) · Movement Disorders · doi:10.1002/mds.870050317 · Cited by 41 · see citing works
L-acetylcarnitine treatment of mental decline in the elderly.
Salvioli, G., & Neri, M. (1994) · PubMed · Cited by 40 · see citing works
Acetyl-L-carnitine in the treatment of mildly demented elderly patients.
Passeri, M., Cucinotta, D., Bonati, P., Iannuccelli, M., Parnetti, L., & Senin, U. (1990) · PubMed · Cited by 36 · see citing works
Action of Acetyl‐L‐Carnitine in Neurodegeneration and Alzheimer's Disease
Calvani, M., Carta, A., Benedetti, N., Iannuccelli, M., & Caruso, G. (1992) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1992.tb38710.x · Cited by 32 · see citing works
Acetyl-Carnitine and Alzheimer's Disease
Bowman, B. A. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.1992.tb01306.x · Cited by 29 · see citing works
Acetyl‐l‐Carnitine: A Drug Able to Slow the Progress of Alzheimer's Disease?
Carta, A., & Calvani, M. (1991) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1991.tb00223.x · Cited by 23 · see citing works
Amitriptyline and clomipramine activate Gi-protein signaling pathway in the induction of analgesia
Ghelardini, C., Galeotti, N., & Bartolini, A. (2001) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-001-0496-8 · Cited by 22 · see citing works
Acetyl‐L‐Carnitine in dementia
Livingston, G., Sax, K., McClenahan, Z., Blumenthal, E., Foley, K., Willison, J. R., MANN, A. H., & James, I. M. (1991) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.930061205 · Cited by 22 · see citing works
Active avoidance learning in old rats chronically treated with levocarnitine acetyl
Ghirardi, O., Caprioli, A., Milano, S., Giuliani, A., Ramacci, M. T., & Angelucci, L. (1992) · Physiology & Behavior · doi:10.1016/0031-9384(92)90451-7 · Cited by 19 · see citing works
Cucinotta, D., Passeri, M., Ventura, S., Lannuccelli, M., Senin, U., Bonati, P. A., & Parnetti, L. (1988) · Drug Development Research · doi:10.1002/ddr.430140310 · Cited by 19 · see citing works
Passeri, M., Iannuccelli, M., Ciotti, G., Bonati, P. A., Nolfe, G., & Cucinotta, D. (1988) · PubMed · Cited by 13 · see citing works
Herrmann, W. M., Dietrich, B., & Hiersemenzel, R. (1990) · PubMed · Cited by 13 · see citing works
Efficacy and Clinical Relevance of Cognition Enhancers
Herrmann, W. M., & Stephan, K. (1991) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199100051-00003 · Cited by 11 · see citing works
[Effects of L-acetylcarnitine on mental deterioration in the aged: initial results].
Cipolli, C., & Chiari, G. (1990) · PubMed · Cited by 11 · see citing works
Neuropsychological changes in demented patients treated with acetyl-L-carnitine.
Sinforiani, E., Iannuccelli, M., Mauri, M. F., Costa, A. C., Merlo, P., Bono, G., & Nappi, G. (1990) · PubMed · Cited by 10 · see citing works
Effects of acetyl-L-carnitine on reaction times in patients with cerebrovascular insufficiency.
Arrigo, A., Casale, R., Buonocore, M., & Ciano, C. (1990) · PubMed · Cited by 9 · see citing works
[The use of 1-acetylcarnitine in (presenile and senile) Alzheimer's disease. Preliminary results].
Acierno, G. (1983) · PubMed · Cited by 6 · see citing works
Acetyl-l-carnitine activity in senile dementia Alzheimer type
Postacchini, D. (1990) · Neurobiology of Aging · doi:10.1016/0197-4580(90)90932-p · Cited by 5 · see citing works
A 1-year controlled trial of acetyl- l -carnitine in early-onset AD
Barrett, A. M. (2001) · Neurology · doi:10.1212/wnl.56.3.425 · Cited by 4 · see citing works
An example of a clinical trial in patients with Alzheimer's disease: some methodological issues.
Lucca, U., Menasce, G., Comelli, M., Cizza, G., Bressi, S., Frattura, L., Tiraboschi, P., & Spagnoli, A. (1989) · PubMed · Cited by 3 · see citing works
Genazzani, E. (1990) · PubMed · Cited by 3 · see citing works
[Methodology of a clinical controlled study of L-acetylcarnitine].
Neri, M., Cortelloni, C., & De Vreese, L. (1990) · PubMed · Cited by 3 · see citing works
Costa, A. C., Martignoni, E., Bono, G., Sinforiani, E., Petraglia, F., Genazzani, A. R., & Nappi, G. (1993) · Florence Research (University of Florence) · Cited by 3 · see citing works
L-acetylcarnitine and Alzheimer's disease: Results of a controlled clinical trial
Spagnoli, A. (1990) · Neurobiology of Aging · doi:10.1016/0197-4580(90)90923-n · Cited by 3 · see citing works
Methodology of a controlled clinical study for cerebral aging evaluation.
Vecchi, G., Neri, M., Cortelloni, C., VREESE, L. D., Sirotti, C., Cipolli, C., Fabbri, L. M., & Zerbini, O. (1990) · PubMed · Cited by 2 · see citing works
Arrigo, A., Clano, E., Casale, R., & Buonocore, M. (1988) · Clinical Trials · Cited by 2 · see citing works
Amaducci, L. A., & Lippi, A. (1991) · PubMed · Cited by 1 · see citing works
Flagged first, then by citations
5 of the 58 references couldn’t be matched to a known paper.
Research works printed but not linked: 5
- Battistin L, Pizzolato G, Dam M, Ponza I, Perlotto N, Bergamo LC, Furlanut M De, Ziliotto R, Bardin G, Chinaglia L, Ferro Milione F, Lorizio A, Luria E, Ravenna C, Toso V, Zanetti R, Bendetti N, Calvani M. Effects of acetyl-L-carnitine (ALC) treatment in dementia: A multicentric, randomized, double-blind study. New Trends in Clinical Neuropharmacology 1989;3(2):131-2.
- Bowman 1992 {published data only} Bowman BAB. Acetyl-carnitine and Alzheimer's disease. Nutrition Reviews 1992;50(5):142-4.
- Bravi 1994 {unpublished data only} Bravi D, Koch G, Calvani M, Bacchieri A, Pola P, NiBhuachalla S, Carta A. A meta-analysis evaluation of clinical trials in Alzheimer's Patients treated with Acetyl-l-carnitine. Society for Neuroscience Abstracts. 1991; Vol. 20:1778.
- Aureli T, Capuani G, Micchelli O, Ghirardi O, Ramacci MT, Conti E. Changes in brain memebrane phospholipid composition during aging: Effect of Acetyl-l-carnitine. Journal of Neurochemistry 1991;57(Suppl):S115.
- Bella R, Bondi R, Raffaelle R, Pennisi G. Effect of acetylcarnitine on geriatric patients suffering from dysthymic disorders. International Journal of Clinical Pharmacological Research 1990.
Cited by
Sorted by citations
ESPEN guidelines on nutrition in dementia
Volkert, D., Chourdakis, M., Faxen-Irving, G., Frühwald, T., Landi, F., Suominen, M. H., Vandewoude, M., Wirth, R., & Schneider, S. M. (2015) · Clinical Nutrition · doi:10.1016/j.clnu.2015.09.004 · Cited by 442 · see citing works
Yin, F. (2023) · The FEBS Journal · doi:10.1111/febs.16344 · Cited by 441 · see citing works
Mitochondria: A therapeutic target in neurodegeneration
Moreira, P. I., Zhu, X., Wang, X., Lee, H., Nunomura, A., Petersen, R. B., Perry, G. L., & Smith, M. A. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.10.007 · Cited by 286 · see citing works
Effective Pharmacologic Management of Alzheimer’s Disease
Farlow, M. R., & Cummings, J. L. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.08.036 · Cited by 225 · see citing works
Alzheimer's Disease: A Lesson from Mitochondrial Dysfunction
Moreira, P. I., Santos, M. S., & Oliveira, C. R. (2007) · Antioxidants and Redox Signaling · doi:10.1089/ars.2007.1703 · Cited by 150 · see citing works
Liu, J., & Ames, B. N. (2005) · Nutritional Neuroscience · doi:10.1080/10284150500047161 · Cited by 138 · see citing works
Oxidative stress: A bridge between Down's syndrome and Alzheimer's disease
Zana, M., Janka, Z., & Kalman, J. L. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.008 · Cited by 137 · see citing works
Sarris, J. J., Papakostas, G. I., Vitolo, O. V., D, M. F. M., & Mischoulon, D. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.03.041 · Cited by 126 · see citing works
The effect of N-acetylcysteine (NAC) on human cognition – A systematic review
Skvarc, D., Dean, O. M., Byrne, L. K., Gray, L. J., Lane, S. E., Lewis, M., Fernandes, B. S., Berk, M., & Marriott, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.04.013 · Cited by 108 · see citing works
Delaying the Mitochondrial Decay of Aging with Acetylcarnitine
Ames, B. N., & Liu, J. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1320.010 · Cited by 103 · see citing works
The Treatment of Alzheimer Disease
Winslow, B. T., Onysko, M. K., Stob, C. M., & Hazlewood, K. A. (2008) · Springer eBooks · doi:10.1007/978-3-540-87523-9_6 · Cited by 100 · see citing works
Serum Levels of Acyl-Carnitines along the Continuum from Normal to Alzheimer's Dementia
Cristofano, A., Sapere, N., la Marca, G., Angiolillo, A., Vitale, M., Corbi, G., Scapagnini, G., Intrieri, M., Russo, C., Corso, G., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155694 · Cited by 95 · see citing works
Smeland, O. B., Meisingset, T. W., Borges, K., & Sonnewald, U. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.04.008 · Cited by 88 · see citing works
Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update
Pennisi, M., Lanza, G., Cantone, M., D’Amico, E., Fisicaro, F., Puglisi, V., Vinciguerra, L., Bella, R., Vicari, E., & Malaguarnera, G. (2020) · Nutrients · doi:10.3390/nu12051389 · Cited by 87 · see citing works
A metabolic and functional overview of brain aging linked to neurological disorders
Baquer, N. Z., Taha, A., Kumar, P., McLean, P., Cowsik, S. M., Kale, R. K., Singh, R., & Sharma, D. (2009) · Biogerontology · doi:10.1007/s10522-009-9226-2 · Cited by 87 · see citing works
Preventive Role of L-Carnitine and Balanced Diet in Alzheimer’s Disease
Kępka, A., Ochocińska, A., Borzym‐Κluczyk, M., Skorupa, E., Stasiewicz‐Jarocka, B., Chojnowska, S., & Waszkiewicz, N. (2020) · Nutrients · doi:10.3390/nu12071987 · Cited by 77 · see citing works
Cognitive decline as a manifestation of mitochondrial disorders (mitochondrial dementia).
Finsterer, J. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.05.011 · Cited by 64 · see citing works
Biochemical deficits and cognitive decline in brain aging: Intervention by dietary supplements
Poddar, J., Pradhan, M., Ganguly, G., & Chakrabarti, S. (2018) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2018.04.002 · Cited by 62 · see citing works
Alternative Medicine and Alzheimer Disease
Kelley, B. J., & Knopman, D. S. (2008) · The Neurologist · doi:10.1097/nrl.0b013e318172cf4d · Cited by 61 · see citing works
Oyanagi, E., Yano, H., Uchida, M., Utsumi, K., & Sasaki, J. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.07.039 · Cited by 60 · see citing works
Bigford, G. E., & Rossi, G. D. (2014) · Advances in Nutrition · doi:10.3945/an.113.005264 · Cited by 59 · see citing works
Shea, T. B. (2007) · Neuromolecular medicine · doi:10.1007/s12017-007-8005-y · Cited by 59 · see citing works
Fink, M. A., Paland, H., Herzog, S., Grube, M., Vogelgesang, S., Weitmann, K., Bialke, A., Hoffmann, W. U., Rauch, B. H., Schroeder, H. W. S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2380 · Cited by 54 · see citing works
Therapeutic approaches in the improvement of cognitive performance in Down syndrome
de la Torre, R., & Dierssen, M. (2012) · Progress in Brain Research · doi:10.1016/b978-0-444-54299-1.00001-7 · Cited by 53 · see citing works
Natural antioxidants and neurodegenerative diseases
Bastianetto, S. (2004) · Frontiers in bioscience · doi:10.2741/1493 · Cited by 51 · see citing works
Therapeutic options in Alzheimer’s disease
Moreira, P. I., Zhu, X., Nunomura, A., Smith, M. A., & Perry, G. L. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.6.897 · Cited by 43 · see citing works
Vascular factors and prevention of dementia
Stephan, B. C. M., & Brayne, C. (2008) · International Review of Psychiatry · doi:10.1080/09540260802094456 · Cited by 41 · see citing works
Treatments for Alzheimer Disease
Potyk, D. K. (2005) · Southern Medical Journal · doi:10.1097/01.smj.0000166671.86815.c1 · Cited by 37 · see citing works
Acetyl-Carnitine and Alzheimer's Disease
Bowman, B. A. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.1992.tb01306.x · Cited by 29 · see citing works
Martinotti, G., Reina, D., Nicola, M. D., Andreoli, S., Tedeschi, D., Ortolani, I., Pozzi, G., Iannoni, E., D'Iddio, S., & Janiri, L. (2010) · Alcohol and Alcoholism · doi:10.1093/alcalc/agq039 · Cited by 26 · see citing works
Lower plasma choline levels are associated with sleepiness symptoms
Pak, V. M., Dai, F., Keenan, B. T., Gooneratne, N. S., & Pack, A. I. (2017) · Sleep Medicine · doi:10.1016/j.sleep.2017.10.004 · Cited by 24 · see citing works
Soczynska, J. K., Kennedy, S. H., Chow, C. S., Woldeyohannes, H. O., Konarski, J. Z., & McIntyre, R. S. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.6.827 · Cited by 23 · see citing works
Khan, Z., Mehan, S., Saifi, M. A., Gupta, G. D., Narula, A. S., & Kalfin, R. E. (2023) · Current Alzheimer Research · doi:10.2174/0115672050289946240223050737 · Cited by 20 · see citing works
L-carnitine for cognitive enhancement in people without cognitive impairment
Chen, N., Yang, M., Zhou, M., Xiao, J., Guo, J., & He, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009374.pub3 · Cited by 19 · see citing works
Neuronutrition: An Emerging Concept
Topçuoğlu, M. A., & Arsava, E. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-53171-7_10 · Cited by 19 · see citing works
Fišar, Z., Hroudová, J., Singh, N., Kopřivová, A., & Maceckova, D. (2016) · Folia Biologica · doi:10.14712/fb2016062020053 · Cited by 18 · see citing works
Nanoparticle-conjugated nutraceuticals exert prospectively palliative of amyloid aggregation
Kanubaddi, K. R., Yang, S.-H., Wu, L.-W., Lee, C., & Weng, C. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s179484 · Cited by 17 · see citing works
Over the Counter Supplements for Memory: A Review of Available Evidence
Hersant, H., He, S., Maliha, P., & Grossberg, G. T. (2023) · CNS Drugs · doi:10.1007/s40263-023-01031-6 · Cited by 16 · see citing works
Lodeiro, M., Ibáñez, C., Cifuentes, A., Simó, C., & Cedazo-Mı́nguez, Á. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132063 · Cited by 16 · see citing works
Hadera, M. G., McDonald, T. S., Smeland, O. B., Meisingset, T. W., Eloqayli, H., Jaradat, S. A., Borges, K., & Sonnewald, U. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1728-5 · Cited by 16 · see citing works
Kang, M., Lee, D. B., Kwon, S., Lee, E. M., & Kim, W. J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164661 · Cited by 15 · see citing works
Frisoni, G. B., Canu, E., Geroldi, C., Brignoli, B., Anglani, L., Galluzzi, S., Zacchi, V., & Zanetti, O. O. (2007) · Aging Clinical and Experimental Research · doi:10.1007/bf03324714 · Cited by 15 · see citing works
Carnitine in Alcohol Use Disorders: A Scoping Review
Bota, A. B., Simmons, J.-G., DiBattista, A., & Wilson, K. R. (2021) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14568 · Cited by 13 · see citing works
Yang, Y., Choi, H., Lee, C., Kim, Y. B., & Kwak, Y. T. (2018) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2018.17.1.1 · Cited by 11 · see citing works
Maynard, S., & Gelblum, J. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s49895 · Cited by 11 · see citing works
Cerebral metabolic effects of acetyl-l-carnitine in rats during aging
Freo, U., Dam, M., & Ori, C. (2008) · Brain Research · doi:10.1016/j.brainres.2008.12.025 · Cited by 10 · see citing works
A Step Back in Time: Is There a Place for Older Drugs in the Treatment of Dementia?
Belgeri, M. T., & Morley, J. E. (2004) · The Journals of Gerontology Series A · doi:10.1093/gerona/59.10.m1025 · Cited by 10 · see citing works
Lee, W., & Kim, M. (2024) · Medicine · doi:10.1097/md.0000000000038067 · Cited by 9 · see citing works
Goldman, D., Warbeck, C. B., Barbaro, R., Khambatta, C., & Nagra, M. (2025) · Nutrients · doi:10.3390/nu17030525 · Cited by 9 · see citing works
Acetyl-L-carnitine and Amyotrophic Lateral Sclerosis: Current Evidence and Potential use
Marchi, F. D., Venkatesan, S., Saraceno, M., Mazzini, L., & Grossini, E. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527322666230330083757 · Cited by 9 · see citing works
Krause, D., & Roupas, P. (2017) · Functional Foods in Health and Disease · doi:10.31989/ffhd.v7i10.370 · Cited by 7 · see citing works
Acetyl-l-carnitine affects nonassociative learning processes in the leech Hirudo medicinalis
Ristori, C., Cataldo, E., Zaccardi, M. L., Traina, G., Calvani, M., Lombardo, P., Scuri, R., & Brunelli, M. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.07.002 · Cited by 7 · see citing works
L-acetylcarnitine for treating fragile X syndrome
Rueda, J.-R., Guillén, V., Ballesteros, J., Tejada, M., & Solà, I. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010012.pub2 · Cited by 6 · see citing works
Future Treatment of Alzheimer Disease
Keskin, A. O., Durmaz, N., Uncu, G., Erzurumluoglu, E., Yıldırım, Z., Tuncer, N., & Adapınar, D. Ö. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.85096 · Cited by 6 · see citing works
Kumar, A., Ghosh, A., Mondal, D., Ghosh, R., & Bandyopadhyay, P. (2017) · International Journal of Current Microbiology and Applied Sciences · doi:10.20546/ijcmas.2017.608.256 · Cited by 6 · see citing works
Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men
Kerksick, C. M. (2024) · Nutrients · doi:10.3390/nu16234240 · Cited by 5 · see citing works
“Currently, research findings are mixed regarding A-GPC’s potential to impact cognition [7,8].”
Functional foods and cognition
Scholey, A. B., Camfield, D., Owen, L., Pipingas, A., & Stough, C. K. K. (2011) · Elsevier eBooks · doi:10.1533/9780857092557.2.277 · Cited by 5 · see citing works
Dietary Supplements: Current Knowledge and Future Frontiers
Costello, R. B., Leser, M., & Coates, P. M. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-385-5_28 · Cited by 4 · see citing works
Glucose hypometabolism and hyperphosphorylated Tau synergistically drive neuronal necroptosis
Chen, X., Li, S., Neubauer, A., Li, X., Mao, W., Brendel, M., Liu, J., Zhang, M., Yang, C., 许瑞胜, et al. (2026) · Neuron · doi:10.1016/j.neuron.2026.03.035 · Cited by 3 · see citing works
Application of Metabolomics to Multiple Chemical Sensitivity Research
Katoh, T., FUJIWARA, Y., Nakashita, C., Lu, X., Hisada, A., Miyazaki, W., Azuma, K., Tanigawa, M., Uchiyama, I., & Kunugita, N. (2016) · Nippon Eiseigaku Zasshi (Japanese Journal of Hygiene) · doi:10.1265/jjh.71.94 · Cited by 3 · see citing works
Medical Foods and Dietary Approaches in Cognitive Decline, Mild Cognitive Impairment, and Dementia
Galvin, J. E. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407824-6.00031-8 · Cited by 2 · see citing works
L-carnitine for cognitive enhancement in people without cognitive impairment
Chen, N., Yang, M., Zhou, M., Xiao, J., Guo, J., He, L., & Xing, R. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009374.pub2 · Cited by 2 · see citing works
Wang, W., Liu, M., Wang, Z., Ye, W., & Li, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1460278 · Cited by 1 · see citing works
Caution with complementaries for cognitive impairment
Harvey, K. J., & Stough, C. K. K. (2011) · Australian Prescriber · doi:10.18773/austprescr.2011.013 · Cited by 1 · see citing works
The role of L-carnitine in preventing mitochondrial dysfunction after neonatal hypoxia -ischemia
Rau, T. (2007) · The Mathematics Enthusiast · Cited by 1 · see citing works
L-acetylcarnitine for fragile X syndrome
Rueda, J.-R., Guillén, V., Ballesteros, J., Tejada, M., & Solà, I. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010012 · Cited by 1 · see citing works
Ayoub, S. (2007) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-9327 · Cited by 1 · see citing works
Kang, M., Lee, D. B., Kwon, S., Lee, E. M., & Kim, W. J. (2022) · Research Square · doi:10.21203/rs.3.rs-1317818/v1 · Cited by 1 · see citing works
Meðferðarúrræði við Alzheimerssjúkdómnum : lyf og lyfleysur
Árnadóttir, E. S. (2014)
Dementia Treatment: Let the Evidence Lead us
Demaerschalk, B. M., Woodruff, B. K., & Caselli, R. J. (2007) · Wiley eBooks · doi:10.1002/9780470988350.ch19
Effective Pharmacologic Management of
Farlow, M. R., & Cummings, J. L. (2007)
The Potential Application of Antioxidant Agents in Alzheimer Disease Therapeutics
Moreira, P. I., Smith, M. A., Zhu, X., Nunomura, A., & Perry, G. L. (2007) · Springer eBooks · doi:10.1007/978-0-387-71522-3_12
Research Priorities for Complementary Medicine in Australia
Bensoussan, A. (2013)
Dietary Supplements—A Classification and Overview of Uses and Efficacy
Webb, G. P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.13971-x
Neurodegenerative Diseases: Parkinson’s and Alzheimer’s Diseases
Ellenstein, A., Prather, C. P., & Коган, М. И. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190466268.003.0020
Anti-Oxidants and Neurodegenerative Disorders
Songer, J. E. (2003)
What are the benefits and harms of acetyl-l-carnitine for older people with dementia?
Tort, S., & Burch, J. (2020) · Cochrane Clinical Answers · doi:10.1002/cca.3471
Alternative Therapies in Dementia
Lipton, A. M., & Marshall, C. D. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4163-2_9
Kang, M., Lee, D. B., Kwon, S., Lee, E. M., & Kim, W. J. (2022) · Research Square · doi:10.21203/rs.3.rs-1317818/v2
(2011) · Australian Prescriber · doi:10.18773/austprescr.2011.014
Endogenous molecules in neuroprotection: Acetyl-L-carnitine
Maldonado, C., Guevara, N., Acuña, S., Fagiolino, P. L., & Vázquez, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23763-8.00056-7
Dietary supplements may boost memory, but more evidence is required
Kang, C. (2024) · Drugs & Therapy Perspectives · doi:10.1007/s40267-024-01070-z
The Effect of Acylcarnitines on Cognitive Function: A Two‐Sample Mendelian Randomization Study
Luan, S., Zhang, J., Wang, C., Wang, Z., & Zhou, J. (2025) · Brain and Behavior · doi:10.1002/brb3.70646
Nakayama, N. (2026) · Springer eBooks · doi:10.1007/978-981-95-7797-2_3
- Authors
- Hudson, S. A., & Tabet, N.
- Affiliations
- Stoke Mandeville Hospital (GB)
- University of Brighton (GB)
- ORCID
- Tabet, Naji
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2003-04-22
- Volume
- 2010
- Issue
- 1
- Pages
- CD003158-CD003158
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- PMC
- PMC6991156
- OpenAlex
- W1589659473
- Cited by
- 86
- References
- 58
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 5 · 2023: 3 · 2022: 4 · 2021: 1 · 2020: 3 · 2019: 2 · 2018: 3 · 2017: 8 · 2016: 3 · 2015: 4 · 2014: 5 · 2013: 2 · 2012: 4
- FWCI
- 0.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cochrane Database of Systematic Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neurological Disorders and Treatments
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Keywords
- acetyl-L-carnitine, dementia, Alzheimer's disease, cognitive decline, cholinergic system, clinical global impression, functional capacity, treatment efficacy, placebo comparison, memory impairment, mitochondrial function
- MeSH terms
- Acetylcarnitine, Aged, Alzheimer Disease, Dementia, Humans, Randomized Controlled Trials as Topic, Nootropic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
